Wir haben ausgewählte Abstracts von unseren Partnern für Sie zusammengestellt.
AbbVie AG
RISANKIZUMAB
UPADACITINIB
- 1370 | Upadacitinib vs TNFi and Other JAKi Treatment Outcomes in Australian Rheumatoid Arthritis Patients: Descriptive Comparison of Persistence and Effectiveness Using the OPAL Dataset
- 1380 | Rapid, Clinically Meaningful Pain Improvements Are Associated with Improvements in Other Patient-Reported Outcomes in RA Patients Treated with Upadacitinib
- 1362 | Comparative Effectiveness of Upadacitinib versus Other JAK Inhibitors in Patients with Rheumatoid Arthritis in a Global Real-World Setting
- 0601 | Early Improvement of Pain, Long-Term Disease Control, and Quality of Life Outcomes in Patients with Psoriatic Arthritis Treated with Upadacitinib
AstraZeneca AG
ANIFROLUMAB
- L13 | Anifrolumab Long-Term Treatment is More Effective Against Organ Damage Than Standard of Care Alone: Results From an External Control Arm Study on Organ Damage in Phase 3 Clinical Trials and The University of Toronto Lupus Clinic Cohort
- 2431 | DORIS Remission in Patients With SLE Treated With Anifrolumab: Post Hoc Analysis From TULIP-1 and TULIP-2 Trials In Patents With no Reported History of Prior Immunosuppressant Use
- 1555 | Sustained Functional Assessment of Chronic Illness Therapy–Fatigue Response in Patients With SLE Receiving Anifrolumab Alongside Standard Therapy
- 1495 | Real-World Reduction in Disease Flares and Oral Corticosteroid Use with Anifrolumab Therapy in Systemic Lupus Erythematosus: A Claims-Based Study
- 2438 | Reduction in Oral Corticosteroid Use During Anifrolumab Therapy: Observations From a Real-world Cohort of Adults with Systemic Lupus Erythematosus
CSL Vifor
AVACOPAN
- 2478 | Avacopan versus a Prednisone Taper in Patients with ANCA-Associated Vasculitis Without Kidney Involvement in a Phase 3 Trial
- 2481 | General, Nervous System, Eye, and Skin Involvement in the Phase 3 Trial of Avacopan for the Treatment of ANCA-Associated Vasculitis
- 2489 | Avacopan for Granulomatosis with Polyangiitis (GPA) and Microscopic Polyangiitis (MPA) in a Real-World Setting
- 2484 | Real-World Use of Avacopan for ANCA-Associated Vasculitis Beyond 52 Weeks
- 1603 | Antineutrophil Cytoplasmic Autoantibody Levels in Patients in the Avacopan Phase 3 Trial
Eli Lilly
IXEKIZUMAB
- 2356 | Baseline Characteristics of Patients with Psoriatic Arthritis Treated with Ixekizumab or Interleukin-23 Inhibitors and Interim Effectiveness Results from an Observational Study in the US
- 0585 | Cycling to TNFi vs. Switching to IL-17Ai After a First TNFi Discontinuation Among Patients with PsA and axSpA: The CorEvitas PsA/SpA Registry
- 1479 | Effectiveness of B/tsDMARDs Including Ixekizumab Per Line of Therapy and Concomitant CsDMARDs in Psoriatic Arthritis: Real-World Data from a Prospective Observational Study
- 1470 | Patients with Psoriatic Arthritis from a Phase 4 Head-to-Head Study Stratified by Nail Involvement
Novartis Pharma Schweiz AG
SECUKINUMAB
- 0589 | Time to Clinical Response to Secukinumab Across Disease Domains Among Patients with Psoriatic Arthritis: A Pooled Post Hoc Analysis of 4 Phase 3 Trials
- 2586 | Results from the Biopsy Driven Ebio Study: Entheseal Tissue Signature in Response to IL-17 Blockade in Psoriatic Arthritis
- 0818 | Defining BASDAI Cut-offs for Disease Activity States in Axial Spondylarthritis – Results from the EuroSpA Collaboration
- 0393 | Effectiveness of Secukinumab in TMJ Symptoms in Children with JPsA and ERA: A Secondary Data Analysis of JUNIPERA
DISEASE AWARENESS
Sandoz Pharmaceuticals AG
ETANERCEPT
UCB Pharma AG
BIMEKIZUMAB
- 0591 | Bimekizumab maintained efficacy responses in patients with active psoriatic arthritis: Up to 2-year results from two phase 3 studies
- 0597 | Bimekizumab maintained stringent clinical responses through Week 104 in patients with axial spondyloarthritis: 2-year results from two phase 3 studies
- 2351 | Low uveitis rates in patients with axial spondyloarthritis or psoriatic arthritis treated with bimekizumab: Long-term results from pooled phase 2b/3 trials
- 2367 | Updated long-term safety and tolerability of bimekizumab in patients with axial spondyloarthritis and psoriatic arthritis: Pooled results from phase 2b/3 studies
- 2348 | Bimekizumab efficacy and safety through 4 years in moderate to severe plaque psoriasis: Long-term results from a phase 3 study and open-label extension